Physician profile

Marc Kalan

Tarzana, CA

NPI 1235364829

$623.66

in general payments reported to CMS, 2019-2025

7 companies · $54.78 in 2025

The $54.78 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$239.21
Education$12.73

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ferring Pharmaceuticals INC. $320.56 2019-2025 Menopur
Emd Serono, INC. $151.40 2020-2025
Merck Sharp & Dohme LLC $56.24 2019-2020
Organon LLC $51.95 2021-2022
Hologic Sales and Service, LLC $17.45 2021
Therapeuticsmd, INC. $14.37 2020
Glaxosmithkline, LLC. $11.69 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marc Kalan

$623.66

in general payments reported 2019-2025

Years
2019-2025
Top company
Ferring Pharmaceuticals INC.
Context
The $54.78 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/283429/marc-kalan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.